Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells

Biochemical Pharmacology

Volumn 96, Issue 4, 2015, Pages 315-322

  Wang, Yongjun ^a   Kojetin, Douglas ^b   Burris, Thomas P ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cell cycle; Circadian rhythm; Heme; Nuclear receptor; Steroid receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; NUCLEAR RECEPTOR NR1D1; SR 9011; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; NR1D1 PROTEIN, HUMAN; PYRROLIDINE DERIVATIVE; SR9011; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; DRUG TARGETING; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; AGONISTS; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; FEMALE; HUMANS; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; PYRROLIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; THIOPHENES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84938288676     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.06.010     Document Type: Article

References (43)

1. S. Raghuram, K.R. Stayrook, P. Huang, P.M. Rogers, A.K. Nosie, D.B. McClure, L.L. Burris, S. Khorasanizadeh, T.P. Burris, and F. Rastinejad Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta Nat. Struct. Mol. Biol. 14 2007 1207 1213
2. L. Yin, N. Wu, J.C. Curtin, M. Qatanani, N.R. Szwergold, R.A. Reid, G.M. Waitt, D.J. Parks, K.H. Pearce, G.B. Wisely, and M.A. Lazar Rev-erb{alpha}, a heme sensor that coordinates metabolic and circadian pathways Science 318 2007 1786 1789
3. T.P. Burris Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock Mol. Endocrinol. 22 2008 1509 1520
4. L. Yin, N. Wu, and M.A. Lazar Nuclear receptor Rev-erbalpha: a heme receptor that coordinates circadian rhythm and metabolism Nucl. Recept. Signal 8 2010 e001
5. H. Duez, and B. Staels Rev-erb-alpha: an integrator of circadian rhythms and metabolism J. Appl. Physiol. 107 2009 1972 1980
6. Q.J. Meng, A. McMaster, S. Beesley, W.Q. Lu, J. Gibbs, D. Parks, J. Collins, S. Farrow, R. Donn, D. Ray, and A. Loudon Ligand modulation of REV-ERB{alpha} function resets the peripheral circadian clock in a phasic manner J. Cell Sci. 121 2008 3629 3635
7. D. Grant, L. Yin, J.L. Collins, D.J. Parks, L.A. Orband-Miller, G.B. Wisely, S. Joshi, M.A. Lazar, T.M. Willson, and W.J. Zuercher GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα ACS Chem. Biol. 5 2010 925 932
8. D. Kojetin, Y. Wang, T.M. Kamenecka, and T.P. Burris Identification of SR 8278, a synthetic cntagonist of the nuclear heme receptor REV-ERB ACS Chem. Biol. 6 2011 131 134
9. N. Kumar, L.A. Solt, Y. Wang, P.M. Rogers, G. Bhattacharyya, T.M. Kamenecka, K.R. Stayrook, C. Crumbley, Z.E. Floyd, J.M. Gimble, P.R. Griffin, and T.P. Burris Regulation of adipogenesis by natural and synthetic REV-ERB ligands Endocrinology 151 2010 3015 3025
10. L.A. Solt, Y. Wang, S. Banerjee, T. Hughes, D.J. Kojetin, T. Lundasen, Y. Shin, J. Liu, M.D. Cameron, R. Noel, S.-H. Yoo, J.S. Takahashi, A.A. Butler, T.M. Kamenecka, and T.P. Burris Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists Nature 485 2012 62 68
11. R. Noel, X. Song, Y. Shin, S. Banerjee, D. Kojetin, L. Lin, C.H. Ruiz, M.D. Cameron, T.P. Burris, and T.M. Kamenecka Synthesis and SAR of tetrahydroisoquinolines as Rev-erbalpha agonists Bioorg. Med. Chem. Lett. 22 2012 3739 3742
12. S. Banerjee, Y. Wang, L.A. Solt, K. Griffet, M. Kazantizis, A. Amador, B.M. El-Gendy, S. Huitron-Resendiz, A.J. Roberts, Y. Shin, T.M. Kamenecka, and T.P. Burris Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behavior Nat. Commun. 5 2014 575
13. Y. Shin, R. Noel, S. Banerjee, D. Kojetin, X. Song, Y. He, L. Lin, M.D. Cameron, T.P. Burris, and T.M. Kamenecka Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbalpha Bioorg. Med. Chem. Lett. 22 2012 4413 4417
14. E. Woldt, Y. Sebti, L.A. Solt, C. Duhem, S. Lancel, J. Eeckhoute, M.K.C. Hesselink, C. Paquet, S. Delhaye, Y. Shin, T.M. Kamenecka, G. Schaart, P. Lefebvre, R. Neviere, T.P. Burris, P. Schrauwen, B. Staels, and H. Duez Rev-erba modulates skeletal muscle oxidative capacity by regulated mitochondrial biogenesis and autophagy Nat. Med. 19 2013 1039 1046
15. A. Kourtidis, R. Jain, R.D. Carkner, C. Eifert, M.J. Brosnan, and D.S. Conklin An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature Cancer Res. 70 2010 1783 1792
16. M.V. Berridge, P.M. Herst, and A.S. Tan Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction Biotechnol. Annu. Rev. 11 2005 127 152
17. R.C. Leif, J.H. Stein, and R.M. Zucker A short history of the initial application of anti-5-BrdU to the detection and measurement of S phase Cytometry, A 58 2004 45 52 (the journal of the International Society for Analytical Cytology)
18. C. Crumbley, Y. Wang, D.J. Kojetin, and T.P. Burris Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene J. Biol. Chem. 285 2010 35386 35392
19. K.R. Stayrook, P.M. Rogers, R.S. Savkur, Y. Wang, C. Su, G. Varga, X. Bu, T. Wei, S. Nagpal, X.S. Liu, and T.P. Burris Regulation of human 3alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha Mol. Pharmacol. 73 2008 607 612
20. H. Zientek-Targosz, D. Kunnev, L. Hawthorn, M. Venkov, S.I. Matsui, R.T. Cheney, and Y. Ionov Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors Mol. Cancer 7 2008 51
21. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massague, and N.P. Pavletich Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 376 1995 313 320
22. M. Pagano, R. Pepperkok, F. Verde, W. Ansorge, and G. Draetta Cyclin A is required at two points in the human cell cycle EMBO J. 11 1992 961 971
23. D. Coverley, H. Laman, and R.A. Laskey Distinct roles for cyclins E and A during DNA replication complex assembly and activation Nat. Cell Biol. 4 2002 523 528
24. F. Guillaumond, H. Dardente, V. Giguere, and N. Cermakian Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors J. Biol. Rhythms. 20 2005 391 403
25. M. Akashi, and T. Takumi The orphan nuclear receptor ROR alpha regulates circadian transcription of the mammalian core-clock Bmal1 Nat. Struct. Mol. Biol. 12 2005 441 448
26. N. Preitner, F. Damiola, L.L. Molina, J. Zakany, D. Duboule, U. Albrecht, and U. Schibler The orphan nuclear receptor REV-ERB alpha controls circadian transcription within the positive limb of the mammalian circadian oscillator Cell 110 2002 251 260
27. C. Crumbley, and T.P. Burris Direct regulation of CLOCK expression by REV-ERB PLoS ONE 6 2011 e17290
28. E.S. Schernhammer, F. Laden, F.E. Speizer, W.C. Willett, D.J. Hunter, I. Kawachi, and G.A. Colditz Rotating night shifts and risk of breast cancer in women participating in the nurses' health study J. Natl. Cancer Inst. 93 2001 1563 1568
29. E.S. Schernhammer, F. Laden, F.E. Speizer, W.C. Willett, D.J. Hunter, I. Kawachi, C.S. Fuchs, and G.A. Colditz Night-shift work and risk of colorectal cancer in the nurses' health study J. Natl. Cancer Inst. 95 2003 825 828
30. S.P. Megdal, C.H. Kroenke, F. Laden, E. Pukkala, and E.S. Schernhammer Night work and breast cancer risk: a systematic review and meta-analysis Eur. J. Cancer 41 2005 2023 2032
31. J. Hansen Increased breast cancer risk among women who work predominantly at night Epidemiology 12 2001 74 77
32. K. Straif, R. Baan, Y. Grosse, B. Secretan, F. El Ghissassi, V. Bouvard, A. Altieri, L. Benbrahim-Tallaa, V. Cogliano, W.H.O.I.A.R.C. Monograph Carcinogenicity of shift-work, painting, and fire-fighting Lancet Oncol. 8 2007 1065 1066
33. E. Filipski, F. Delaunay, V.M. King, M.W. Wu, B. Claustrat, A. Grechez-Cassiau, C. Guettier, M.H. Hastings, and L. Francis Effects of chronic jet lag on tumor progression in mice Cancer Res. 64 2004 7879 7885
34. P.N. Shah, M.C. Mhatre, and L.S. Kothari Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods Cancer Res. 44 1984 3403 3407
35. E. Filipski, V.M. King, X.M. Li, T.G. Granda, M.C. Mormont, X.H. Liu, B. Claustrat, M.H. Hastings, and F. Levi Host circadian clock as a control point in tumor progression J. Natl. Cancer Inst. 94 2002 690 697
36. S. van den Heiligenberg, P. Depres-Brummer, H. Barbason, B. Claustrat, M. Reynes, and F. Levi The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats Life Sci. 64 1999 2523 2534
37. Y.M. Lin, J.H. Chang, K.T. Yeh, M.Y. Yang, T.C. Li, S.F. Lin, W.W. Su, and J.G. Chang Disturbance of circadian gene expression in hepatocellular carcinoma Mol. Carcinog. 47 2008 925 933
38. S.J. Kuo, S.T. Chen, K.T. Yeh, M.F. Hou, Y.S. Chang, N.C. Hsu, and J.G. Chang Disturbance of circadian gene expression in breast cancer Virchows Arch. 454 2009 467 474
39. S.T. Chen, K.B. Choo, M.F. Hou, K.T. Yeh, S.J. Kuo, and J.G. Chang Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers Carcinogenesis 26 2005 1241 1246
40. X.M. Yang, P.A. Wood, E.Y. Oh, J. Du-Quiton, C.M. Ansell, and W.J.M. Hrushesky Down regulation of circadian clock gene period 2 accelerates breast cancer growth by altering its daily growth rhythm Breast Cancer Res. Treat. 117 2009 423 431
41. J. Wang, and M.A. Lazar Bifunctional role of Rev-erb{alpha} in adipocyte differentiation Mol. Cell Biol. 28 2008 2213 2220
42. C. De Mei, L. Ercolani, C. Parodi, M. Veronesi, C.L. Vecchio, G. Bottegoni, E. Torrente, R. Scarpelli, R. Marotta, R. Ruffili, M. Mattioli, A. Reggiani, M. Wade, and B. Grimaldi Dual inhibition of REV-ERBbeta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells Oncogene 34 2015 2597 2608
43. S. Sitaula, C. Billon, T.M. Kamenecka, L.A. Solt, and T.P. Burris Suppression of atherosclerosis by synthetic REV-ERB agonist Biochem. Biophys. Res. Commun. 460 3 2015 566 571